The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
The role of alternative splicing in cancer: From oncogenesis to drug resistance
Open accessAbstract
Alternative splicing is a tightly regulated process whereby non-coding sequences of pre-mRNA are removed and protein-coding segments are assembled in diverse combinations, ultimately giving rise to proteins with distinct or even opposing functions. In the past decade, whole genome/transcriptome sequencing studies revealed the high complexity of splicing regulation, which occurs co-transcriptionally and is influenced by chromatin status and mRNA modifications. Consequently, splicing profiles of both healthy and malignant cells display high diversity and alternative splicing was shown to be widely deregulated in multiple cancer types. In particular, mutations in pre-mRNA regulatory sequences, splicing regulators and chromatin modifiers, as well as differential expression of splicing factors are important contributors to cancer pathogenesis. It has become clear that these aberrations contribute to many facets of cancer, including oncogenic transformation, cancer progression, response to anticancer drug treatment as well as resistance to therapy. In this respect, alternative splicing was shown to perturb the expression a broad spectrum of relevant genes involved in drug uptake/metabolism (i.e. SLC29A1, dCK, FPGS, and TP), activation of nuclear receptor pathways (i.e. GR, AR), regulation of apoptosis (i.e. MCL1, BCL-X, and FAS) and modulation of response to immunotherapy (CD19). Furthermore, aberrant splicing constitutes an important source of novel cancer biomarkers and the spliceosome machinery represents an attractive target for a novel and rapidly expanding class of therapeutic agents. Small molecule inhibitors targeting SF3B1 or splice factor kinases were highly cytotoxic against a wide range of cancer models, including drug-resistant cells. Importantly, these effects are enhanced in specific cancer subsets, such as splicing factor-mutated and c-MYC-driven tumors. Furthermore, pre-clinical studies report synergistic effects of spliceosome modulators in combination with conventional antitumor agents. These strategies based on the use of low dose splicing modulators could shift the therapeutic window towards decreased toxicity in healthy tissues. Here we provide an extensive overview of the latest findings in the field of regulation of splicing in cancer, including molecular mechanisms by which cancer cells harness alternative splicing to drive oncogenesis and evade anticancer drug treatment as well as splicing-based vulnerabilities that can provide novel treatment opportunities. Furthermore, we discuss current challenges arising from genome-wide detection and prediction methods of aberrant splicing, as well as unravelling functional relevance of the plethora of cancer-related splicing alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Predicting splicing from primary sequence with deep learning
Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J. F., Darbandi, S. F., Knowles, D., Li, Y. I., Kosmicki, J. A., Arbelaez, J., Cui, W., Schwartz, G. B., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.015 · Cited by 2,853
Shen, S., Park, J. W., Lu, Z.-X., Lin, L., Henry, M. D., Wu, Y. N., Zhou, Q., & Xing, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419161111 · Cited by 2,713
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
Expansion of the eukaryotic proteome by alternative splicing
Nilsen, T. W., & Graveley, B. R. (2010) · Nature · doi:10.1038/nature08909 · Cited by 2,197
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
RNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915
The landscape of cancer genes and mutational processes in breast cancer
The Oslo Breast Cancer Consortium (OSBREAC), Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-Zainal, S., Martin, S., Varela, I., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,698
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Spliced segments at the 5′ terminus of adenovirus 2 late mRNA
Berget, S. M., Moore, C., & Sharp, P. A. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.8.3171 · Cited by 1,413
Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP)
Van Nostrand, E. L., Pratt, G. A., Shishkin, A. A., Gelboin-Burkhart, C., Fang, M. Y., Sundararaman, B., Blue, S. M., Nguyen, T. B., Surka, C., Elkins, K., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3810 · Cited by 1,397
Alternative splicing as a regulator of development and tissue identity
Baralle, F. E., & Giudice, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.27 · Cited by 1,333
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA
Chow, L. T., Gelinas, R. E., Broker, T. R., & Roberts, R. J. (1977) · Cell · doi:10.1016/0092-8674(77)90180-5 · Cited by 1,234
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
The human splicing code reveals new insights into the genetic determinants of disease
Xiong, H. Y., Alipanahi, B., Lee, L. J., Bretschneider, H., Merico, D., Yuen, R. K. C., Hua, Y., Gueroussov, S., Najafabadi, H. S., Hughes, T. R., et al. (2015) · Science · doi:10.1126/science.1254806 · Cited by 1,220
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010) · Nature · doi:10.1038/nature08697 · Cited by 1,179
Splicing regulation: From a parts list of regulatory elements to an integrated splicing code
Wang, Z., & Burge, C. B. (2008) · RNA · doi:10.1261/rna.876308 · Cited by 1,086
A day in the life of the spliceosome
Matera, A. G., & Wang, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3742 · Cited by 1,074
The Evolutionary Landscape of Alternative Splicing in Vertebrate Species
Barbosa-Morais, N. L., Irimia, M., Pan, Q., Xiong, H. Y., Gueroussov, S., Lee, L. J., Slobodeniuc, V., Kutter, C., Watt, S., Çolak, R., et al. (2012) · Science · doi:10.1126/science.1230612 · Cited by 1,063
SEQC/MAQC-III Consortium (2014) · Nature Biotechnology · doi:10.1038/nbt.2957 · Cited by 983
Evolutionary Dynamics of Gene and Isoform Regulation in Mammalian Tissues
Merkin, J., Russell, C., Chen, P., & Burge, C. B. (2012) · Science · doi:10.1126/science.1228186 · Cited by 972
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Caesar-Johnson, S. J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 897
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 887
Coupling mRNA processing with transcription in time and space
Bentley, D. L. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3662 · Cited by 828
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 814
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Trincado, J. L., Entizne, J. C., Hysenaj, G., Singh, B., Skalic, M., Elliott, D. J., & Eyras, E. (2018) · Genome Biology · doi:10.1186/s13059-018-1417-1 · Cited by 701
BCL-2 family isoforms in apoptosis and cancer
Warren, C. F. A., Wong-Brown, M. W., & Bowden, N. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1407-6 · Cited by 700
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationSplicing factor SF3b as a target of the antitumor natural product pladienolide
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., & Mizui, Y. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.16 · Cited by 657
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.18 · Cited by 650
Messenger RNA modifications: Form, distribution, and function
Gilbert, W. V., Bell, T. A., & Schaening, C. (2016) · Science · doi:10.1126/science.aad8711 · Cited by 627
Regulation of Apoptosis by Alternative Pre-mRNA Splicing
Schwerk, C., & Schulze-Osthoff, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.05.026 · Cited by 594
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 580
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
Therapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 561
Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers
Supek, F., Miñana, B., Valcárcel, J., Gabaldón, T., & Lehner, B. (2014) · Cell · doi:10.1016/j.cell.2014.01.051 · Cited by 557
The Functional Impact of Alternative Splicing in Cancer
Climente-González, H., Porta-Pardo, E., Godzik, A., & Eyras, E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.012 · Cited by 552
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationRecurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
Harbour, J. W., Roberson, E. D. O., Anbunathan, H., Onken, M. D., Worley, L. A., & Bowcock, A. M. (2013) · Nature Genetics · doi:10.1038/ng.2523 · Cited by 516
Seiler, M., Yoshimi, A., Darman, R., Chan, B., Keaney, G., Thomas, M., Agrawal, A. A., Caleb, B., Csibi, A., Sean, E., et al. (2018) · Nature Medicine · doi:10.1038/nm.4493 · Cited by 507
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationRegulation of splicing by SR proteins and SR protein-specific kinases
Zhou, Z., & Fu, X.-D. (2013) · Chromosoma · doi:10.1007/s00412-013-0407-z · Cited by 478
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J. L., Taylor, M. N., Maughan, B. L., Denmeade, S. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1961 · Cited by 466
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K. H., Peng, S., Aird, D., Bailey, S. L., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 453
Regulation of Alternative Splicing Through Coupling with Transcription and Chromatin Structure
Naftelberg, S., Schor, I. E., Ast, G., & Kornblihtt, A. R. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034242 · Cited by 448
Anczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 447
Seiler, M., Peng, S., Agrawal, A. A., Palacino, J., Teng, T., Zhu, P., Smith, P. G., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.088 · Cited by 444
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Self-citationSF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Furney, S. J., Pedersen, M., Gentien, D., Dumont, A. G., Rapinat, A., Desjardins, L., Turajlic, S., Piperno-Neumann, S., de la Grange, P., Roman-Roman, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0330 · Cited by 434
Detained introns are a novel, widespread class of post-transcriptionally spliced introns
Boutz, P. L., Bhutkar, A., & Sharp, P. A. (2015) · Genes & Development · doi:10.1101/gad.247361.114 · Cited by 425
Cell Motility Is Controlled by SF2/ASF through Alternative Splicing of the Ron Protooncogene
Ghigna, C., Giordano, S., Shen, H., Benvenuto, F., Castiglioni, F., Comoglio, P. M., Green, M. R., Riva, S., & Biamonti, G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.026 · Cited by 389
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
Koh, C. M., Bezzi, M., Low, D. H. P., Ang, W. X., Teo, S. X., Gay, F. P. H., Al-Haddawi, M., Tan, S. Y., Osato, M., Sabò, A., et al. (2015) · Nature · doi:10.1038/nature14351 · Cited by 380
Oakley, R. H., & Cidlowski, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.179325 · Cited by 373
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 370
Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-373159 · Cited by 369
SRSF1-Regulated Alternative Splicing in Breast Cancer
Anczuków, O., Akerman, M., Cléry, A., Wu, J., Shen, C., Shirole, N. H., Raimer, A., Sun, S., Jensen, M. A., Hua, Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.005 · Cited by 367
Splicing and transcription touch base: co-transcriptional spliceosome assembly and function
Herzel, L., Ottoz, D. S. M., Alpert, T., & Neugebauer, K. M. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.63 · Cited by 364
Lee, S. C.-W., Dvinge, H., Kim, E., Cho, H., Micol, J.-B., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347
Widespread intron retention diversifies most cancer transcriptomes
Dvinge, H., & Bradley, R. K. (2015) · Genome Medicine · doi:10.1186/s13073-015-0168-9 · Cited by 344
Intron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339
Alternative Splicing May Not Be the Key to Proteome Complexity
Tress, M. L., Abascal, F., & Valencia, A. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.08.008 · Cited by 339
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338
Molecular basis of antifolate resistance
Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338
Self-citationPavlyukov, M. S., Yu, H., Bastola, S., Minata, M., Shender, V. O., Lee, Y., Zhang, S., Wang, J., Komarova, S., Wang, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.012 · Cited by 320
An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis
Moore, M. J., Wang, Q., Kennedy, C. J., & Silver, P. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.019 · Cited by 316
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationManipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks
Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J.-I., Murray, M. V., Kimura, H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314298200 · Cited by 308
Aberrant RNA Splicing in Cancer
Escobar-Hoyos, L., Knorr, K., & Abdel-Wahab, O. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050407 · Cited by 302
Chen, L., Chen, J.-Y., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 299
The multiple functions of RNA helicases as drivers and regulators of gene expression
Bourgeois, C. F., Mortreux, F., & Auboeuf, D. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.50 · Cited by 290
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
Shirai, C. L., Ley, J. N., White, B. S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., Duncavage, E. J., Okeyo-Owuor, T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.008 · Cited by 287
U2AF1 mutations alter splice site recognition in hematological malignancies
Ilagan, J. O., Ramakrishnan, A., Hayes, B., Murphy, M. E., Zebari, A. S., Bradley, P., & Bradley, R. K. (2015) · Genome Research · doi:10.1101/gr.181016.114 · Cited by 287
Corrionero, A., Miñana, B., & Valcárcel, J. (2011) · Genes & Development · doi:10.1101/gad.2014311 · Cited by 263
Eskens, F. A. L. M., Ramos, F. J., Burger, H., O'Brien, J. P., Piera, A., de Jonge, M. J. A., Mizui, Y., Wiemer, E. A. C., Carreras, M. J., Baselga, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0485 · Cited by 259
Coupling of RNA Polymerase II Transcription Elongation with Pre-mRNA Splicing
Saldi, T., Cortazar, M. A., Sheridan, R. M., & Bentley, D. L. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.04.017 · Cited by 258
Calabretta, S., Bielli, P., Passacantilli, I., Pilozzi, E., Fendrich, V, Capurso, G., Fave, G. D., & Sette, C. (2016) · Oncogene · doi:10.1038/onc.2015.270 · Cited by 249
Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Von Ahrens, D., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 247
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 239
Damm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronné, L., Scourzic, L., Chesnais, V., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400994 · Cited by 231
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication
Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M., Yamamoto, N., Herzenberg, L. A., Herzenberg, L. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604616103 · Cited by 231
Erkelenz, S., Mueller, W. F., Evans, M. S., Busch, A., Schöneweis, K., Hertel, K. J., & Schaal, H. (2013) · RNA · doi:10.1261/rna.037044.112 · Cited by 224
Genome-Wide Analysis of RNA Secondary Structure
Bevilacqua, P. C., Ritchey, L. E., Su, Z., & Assmann, S. M. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-120215-035034 · Cited by 224
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes
Hamard, P.-J., Santiago, G. E., Liu, F., Karl, D. L., Martinez, C., Man, N., Mookhtiar, A. K., Duffort, S., Greenblatt, S., Verdun, R. E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.002 · Cited by 222
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Yoshimi, A., Lin, K.-T., Wiseman, D. H., Rahman, M. A., Pastore, A., Wang, B., Lee, S. C.-W., Micol, J.-B., Zhang, X. J., de Botton, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1618-0 · Cited by 220
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219
Hong, D. S., Kurzrock, R., Naing, A., Wheler, J. J., Falchook, G. S., Schiffman, J. S., Faulkner, N., Pilat, M. J., O’Brien, J., & LoRusso, P. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0046-5 · Cited by 219
Ferreira, P. G., Jares, P., Rico, D., Gómez-López, G., Martínez-Trillos, A., Villamor, N., Ecker, S., González-Pérez, A., Knowles, D. G., Monlong, J., et al. (2014) · Genome Research · doi:10.1101/gr.152132.112 · Cited by 214
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities
Zhang, J., Lieu, Y. K., Ali, A. M., Penson, A., Reggio, K. S., Rabadan, R., Raza, A., Mukherjee, S., & Manley, J. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514105112 · Cited by 208
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Self-citationOncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYC
Das, S., Anczuków, O., Akerman, M., & Krainer, A. R. (2012) · Cell Reports · doi:10.1016/j.celrep.2011.12.001 · Cited by 202
Tauro, B. J., Mathias, R. A., Greening, D. W., Gopal, S. K., Ji, H., Kapp, E. A., Coleman, B. M., Hill, A. F., Kusebauch, U., Hallows, J. L., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.027086 · Cited by 195
Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1802 · Cited by 194
David, C. J., Boyne, A. R., Millhouse, S. R., & Manley, J. L. (2011) · Genes & Development · doi:10.1101/gad.2038011 · Cited by 191
Wu, J. Q., Habegger, L., Noisa, P., Szekely, A., Qiu, C., Hutchison, S., Raha, D., Egholm, M., Lin, H., Weissman, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914114107 · Cited by 189
Li, B., Jiang, J., Assaraf, Y. G., Xiao, H., Chen, Z.-S., & Huang, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100720 · Cited by 188
Self-citationThe Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)
Buxade, M. (2008) · Frontiers in Bioscience · doi:10.2741/3086 · Cited by 184
Aberrant RNA Splicing in Cancer and Drug Resistance
Wang, B.-D., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 182
Targeting mRNA processing as an anticancer strategy
Desterro, J., Bak-Gordon, P., & Carmo-Fonseca, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0042-3 · Cited by 181
Savage, K. I., Gorski, J. J., Barros, E. M., Irwin, G. W., Manti, L., Powell, A. J., Pellagatti, A., Lukashchuk, N., McCance, D. J., McCluggage, W. G., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.021 · Cited by 180
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
Visconte, V., Rogers, H. J., Singh, J., Barnard, J., Bupathi, M., Traina, F., McMahon, J., Makishima, H., Szpurka, H., Jankowska, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430876 · Cited by 179
The Relationship between Alternative Splicing and Proteomic Complexity
Blencowe, B. J. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.04.001 · Cited by 178
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
Yokoi, A., Kotake, Y., Takahashi, K., Kadowaki, T., Matsumoto, Y., Minoshima, Y., Sugi, N. H., Sagane, K., Hamaguchi, M., Iwata, M., et al. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08387.x · Cited by 177
Hintzsche, J. D., Gorden, N. T., Amato, C. M., Kim, J., Wuensch, K. E., Robinson, S. E., Applegate, A. J., Couts, K. L., Medina, T. M., Wells, K. R., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000345 · Cited by 176
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Maguire, S. L., Leonidou, A., Wai, P., Marchiò, C., Ng, C. K., Sapino, A., Salomon, A., Reis‐Filho, J. S., Weigelt, B., & Natrajan, R. C. (2015) · The Journal of Pathology · doi:10.1002/path.4483 · Cited by 175
Structural basis of splicing modulation by antitumor macrolide compounds
Cretu, C., Agrawal, A. A., Cook, A., Will, C. L., Fekkes, P., Smith, P. G., Lührmann, R., Larsen, N., Buonamici, S., & Pena, V. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.011 · Cited by 174
The U1 spliceosomal RNA is recurrently mutated in multiple cancers
Shuai, S., Suzuki, H., Diaz-Navarro, A., Nadeu, F., Kumar, S. A., Gutierrez-Fernandez, A., Delgado, J., Pinyol, M., López-Otín, C., Puente, X. S., et al. (2019) · Nature · doi:10.1038/s41586-019-1651-z · Cited by 171
RNA editing in nascent RNA affects pre-mRNA splicing
Hsiao, Y.-H. E., Bahn, J. H., Yang, Y., Lin, X., Tran, S., Yang, E.-W., Quinones-Valdez, G., & Xiao, X. (2018) · Genome Research · doi:10.1101/gr.231209.117 · Cited by 170
U2AF-homology motif interactions are required for alternative splicing regulation by SPF45
Corsini, L., Bonnal, S., Basquin, J., Hothorn, M., Scheffzek, K., Valcárcel, J., & Sattler, M. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1260 · Cited by 169
Kahles, A., Ong, C. S., Zhong, Y., & Rätsch, G. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw076 · Cited by 168
Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing
Fan, L., Lagisetti, C., Edwards, C. C., Webb, T. R., & Potter, P. M. (2011) · ACS Chemical Biology · doi:10.1021/cb100356k · Cited by 167
Tang, Y., Horikawa, I., Ajiro, M., Robles, A. I., Fujita, K., Mondal, A. M., Stauffer, J. K., Zheng, Z.-M., & Harris, C. C. (2013) · Oncogene · doi:10.1038/onc.2012.288 · Cited by 165
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
Gout, S., Brambilla, E. M., Boudria, A., Drissi, R., Lantuéjoul, S., Gazzéri, S., & Eymin, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046539 · Cited by 163
The ribosome-engaged landscape of alternative splicing
Weatheritt, R. J., Sterne-Weiler, T., & Blencowe, B. J. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3317 · Cited by 162
Folco, E. G., Coil, K. E., & Reed, R. (2011) · Genes & Development · doi:10.1101/gad.2009411 · Cited by 162
Nguyen, H. D., Leong, W. Y., Li, W., Reddy, P. N. G., Sullivan, J. D., Walter, M. J., Zou, L., & Graubert, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3970 · Cited by 161
Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy
Salton, M., & Misteli, T. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.11.005 · Cited by 159
Nojima, T., Rebelo, K., Gomes, T., Grosso, A. R., Proudfoot, N. J., & Carmo‐Fonseca, M. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.004 · Cited by 155
Akgül, C., MOULDING, D. A., & Edwards, S. W. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4001-7 · Cited by 149
Teng, T., Tsai, J., Puyang, X., Seiler, M., Peng, S., Prajapati, S., Aird, D. R., Buonamici, S., Caleb, B. L., Chan, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15522 · Cited by 146
Guharoy, M., Bhowmick, P., Sallam, M., & Tompa, P. (2016) · Nature Communications · doi:10.1038/ncomms10239 · Cited by 145
Adesso, L., Calabretta, S., Barbagallo, F., Capurso, G., Pilozzi, E., Geremia, R., Fave, G. D., & Sette, C. (2012) · Oncogene · doi:10.1038/onc.2012.306 · Cited by 141
Hubert, C. G., Bradley, R. K., Ding, Y., Toledo, C. M., Herman, J., Skutt-Kakaria, K., Girard, E. J., Davison, J., Berndt, J. D., Corrin, P. D., et al. (2013) · Genes & Development · doi:10.1101/gad.212548.112 · Cited by 140
Hatcher, J. M., Wu, G., Zeng, C., Zhu, J., Fan, M., Patel, S. H., Wang, W., Ficarro, S. B., Leggett, A. L., Powell, C. E., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.01.013 · Cited by 135
Kolba, M. D., Dudka, W., Zaręba-Kozioł, M., Kominek, A., Ronchi, P., Turos-Korgul, L., Chrościcki, P., Włodarczyk, J., Schwab, Y., Klejman, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2045-8 · Cited by 134
Shender, V. О., Pavlyukov, M. S., Ziganshin, R., Arapidi, G. P., Kovalchuk, S. I., Anikanov, N. A., Altukhov, I. A., Alexeev, D. G., Butenko, I., Shavarda, A. L., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.041194 · Cited by 130
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1
Zhang, J., Ali, A. M., Lieu, Y. K., Liu, Z., Gao, J., Rabadán, R., Raza, A., Mukherjee, S., & Manley, J. L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.017 · Cited by 129
Nadiminty, N., Tummala, R., Liu, C., Lou, W., Evans, C. P., & Gao, A. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1057 · Cited by 124
RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML
Crews, L. A., Balaian, L., Santos, N. P. D., Leu, H. S., Court, A. C., Lazzari, E., Sadarangani, A., Zipeto, M., Clair, J. J. L., Villa, R., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.003 · Cited by 124
PRPF8 defects cause missplicing in myeloid malignancies
Kurtović-Kozarić, A., Przychodzen, B. P., Singh, J., Konarska, M. M., Clemente, M. J., Otrock, Z. K., Nakashima, M. O., Hsi, E. D., Yoshida, K., Shiraishi, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2014.144 · Cited by 123
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
Shirai, C. L., White, B. S., Tripathi, M., TAPIA-CONYER, R. C., Ley, J. N., Ndonwi, M., Kim, S. P., Shao, J., Carver, A., Sáez, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms14060 · Cited by 122
Schaaij‐Visser, T. B. M., de Wit, M., Lam, S. W., & Jiménez, C. R. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.01.029 · Cited by 119
Nanomedicine to target multidrug resistant tumors
Lepeltier, É., Rijo, P. M., Rizzolio, F., Popovtzer, R., Petrikaitė, V., Assaraf, Y. G., & Passirani, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100704 · Cited by 118
Self-citationInhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
Salton, M., Kasprzak, W. K., Voss, T. C., Shapiro, B. A., Poulikakos, P. I., & Misteli, T. (2015) · Nature Communications · doi:10.1038/ncomms8103 · Cited by 114
Liani, E., Rothem, L., Bunni, M. A., Smith, C. A., Jansen, G., & Assaraf, Y. G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10829 · Cited by 113
Self-citationScheper, G. C., Parra-Palau, J. L., Wilson, M., van Kollenburg, B., Vertegaal, A. C. O., Han, Z., & Proud, C. G. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5692-5705.2003 · Cited by 113
Roles of RNA-Binding Proteins in DNA Damage Response
Kai, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030310 · Cited by 113
Finci, L. I., Zhang, X., Huang, X., Zhou, Q., Tsai, J., Teng, T., Agrawal, A. A., Chan, B., Irwin, S., Karr, C. D., et al. (2018) · Genes & Development · doi:10.1101/gad.311043.117 · Cited by 112
SF3B1 Association with Chromatin Determines Splicing Outcomes
Kfir, N., Lev-Maor, G., Glaich, O., Alajem, A., Datta, A., Sze, S. K., Meshorer, E., & Ast, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.048 · Cited by 111
Combinatorial Genetics Reveals a Scaling Law for the Effects of Mutations on Splicing
Baeza-Centurión, P., Miñana, B., Schmiedel, J. M., Valcárcel, J., & Lehner, B. (2019) · Cell · doi:10.1016/j.cell.2018.12.010 · Cited by 111
Wang, B., Ceniccola, K., Hwang, S., Andrawis, R., Horvath, A., Freedman, J. A., Olender, J., Knapp, S., Ching, T. H., Garmire, L. X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15921 · Cited by 107
Adamia, S., Haibe-Kains, B., Pilarski, P. M., Bar-Natan, M., Pevzner, S., Avet-Loiseau, H., Lode, L., Verselis, S., Fox, E. A., Burke, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0956 · Cited by 106
Larráyoz, M., Blakemore, S. J., Dobson, R. C., Blunt, M. D., Rose-Zerilli, M. J. J., Walewska, R. J., Duncombe, A. S., Oscier, D. G., Koide, K., Forconi, F., et al. (2015) · Leukemia · doi:10.1038/leu.2015.286 · Cited by 106
Vohhodina, J., Barros, E. M., Pfaff, A. L., Liberante, F. G., Manti, L., Bankhead, P., Cosgrove, N. S., Madden, A. F., Harkin, D. P., & Savage, K. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1046 · Cited by 106
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708289 · Cited by 105
ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation
Bhate, A., Parker, D. J., Bebee, T. W., Ahn, J., Arif, W., Rashan, E. H., Chorghade, S., Chau, A., Lee, J.-H., Anakk, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9768 · Cited by 103
Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity
Roy, B., Haupt, L. M., & Griffiths, L. R. (2013) · Current Genomics · doi:10.2174/1389202911314030004 · Cited by 102
Specific inhibition of splicing factor activity by decoy RNA oligonucleotides
Denichenko, P., Mogilevsky, M., Cléry, A., Welte, T., Biran, J., Tepper, O., Barnabas, G. D., Danan-Gotthold, M., Kumar, S., Yavin, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09523-0 · Cited by 102
The alternative splicing side of cancer
Biamonti, G., Catillo, M., Pignataro, D. S., Montecucco, A., & Ghigna, C. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.03.016 · Cited by 101
Post-Transcriptional Regulation of Homeostatic, Stressed, and Malignant Stem Cells
Chua, B. A., van der Werf, I. M., Jamieson, C. H. M., & Signer, R. A. J. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.01.005 · Cited by 101
Albert, B. J., McPherson, P. A., O'Brien, K., Czaicki, N. L., DeStefino, V. J., Osman, S., Li, M., Day, B. W., Grabowski, P. J., Moore, M. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0051 · Cited by 99
Seitz, A. K., Thoene, S., Bietenbeck, A., Nawroth, R., Tauber, R., Thalgott, M. K., Schmid, S. C., Secci, R., Retz, M. M., Gschwend, J. E., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.024 · Cited by 99
Liang, Y., Tebaldi, T., Rejeski, K., Joshi, P. M., Stefani, G., Taylor, A., Song, Y., Vasic, R., Maziarz, J. D., Balasubramanian, K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0152-7 · Cited by 99
Spatial dynamics of TRAIL death receptors in cancer cells
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.001 · Cited by 97
Emerging roles of histone modifications and HDACs in RNA splicing
Rahhal, R., & Seto, E. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz292 · Cited by 97
Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
Cai, J., Damaraju, V. L., Groulx, N., Mowles, D., Peng, Y., Robins, M. J., Cass, C. E., & Gros, P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5528 · Cited by 93
Yin, S., Gambe, R. G., Sun, J., Martinez, A. Z., Cartun, Z. J., Regis, F. F., Wan, Y., Fan, J., Brooks, A. N., Herman, S. E. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.013 · Cited by 93
Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling
de Wit, M., Kant, H., Piersma, S. R., Pham, T. V., Mongera, S., Berkel, M. P. V., Boven, E., Pontén, F., Meijer, G. A., Jiménez, C. R., et al. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.01.001 · Cited by 91
Recurrent SRSF2 mutations in MDS affect both splicing and NMDPreprint
Rahman, M. A., Lin, K., Bradley, R. K., Abdel-Wahab, O. I., & Krainer, A. R. (2020) · Genes & Development · doi:10.1101/gad.332270.119 · Cited by 91
Wojtuszkiewicz, A., Schuurhuis, G. J., Kessler, F. L., Piersma, S. R., Knol, J. C., Pham, T. V., Jansen, G., Musters, R. J. P., van Meerloo, J., Assaraf, Y. G., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.052944 · Cited by 90
Self-citationMost Alternative Isoforms Are Not Functionally Important
Tress, M. L., Abascal, F., & Valencia, A. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.04.002 · Cited by 90
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Adès, L., et al. (2019) · Blood · doi:10.1182/blood-2019-123854 · Cited by 90
Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages
Effenberger, K. A., Urabe, V. K., Prichard, B. E., Ghosh, A. K., & Jurica, M. S. (2016) · RNA · doi:10.1261/rna.053108.115 · Cited by 89
Splicing heterogeneity: separating signal from noise
Wan, Y., & Larson, D. R. (2018) · Genome biology · doi:10.1186/s13059-018-1467-4 · Cited by 89
Alternative Splicing: A Potential Source of Functional Innovation in the Eukaryotic Genome
Chen, L., Tovar-Corona, J. M., & Urrutia, A. O. (2012) · International Journal of Evolutionary Biology · doi:10.1155/2012/596274 · Cited by 87
Shkreta, L., Toutant, J., Durand, M., Manley, J. L., & Chabot, B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.071 · Cited by 87
A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes
Zhou, Q., Derti, A., Ruddy, D. A., Rakiec, D. P., Kao, I., Lira, M., Gibaja, V., Chan, H., Yang, Y., Min, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2930 · Cited by 85
Constitutive splicing and economies of scale in gene expression
Ding, F., & Elowitz, M. B. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0226-x · Cited by 85
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia
Hou, H., Liu, C., Kuo, Y., Chou, W., Tsai, C., Lin, C., Lin, L., Tseng, M., Chiang, Y., Liu, M.-C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7000 · Cited by 84
CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer
Tian, J., Wang, Z., Mei, S., Yang, N., Yang, Y., Ke, J., Zhu, Y., Gong, Y., Zou, D., Peng, X., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky954 · Cited by 84
Kashyap, M. K., Kumar, D., Villa, R., Clair, J. J. L., Benner, C. W., Sasik, R., Jones, H., Ghia, E. M., Rassenti, L. Z., Kipps, T. J., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.122069 · Cited by 83
Raz, S., Stark, M., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.004 · Cited by 81
Self-citationPaolella, B. R., Gibson, W. J., Urbanski, L. M., Alberta, J. A., Zack, T. I., Bandopadhayay, P., Nichols, C. A., Agarwalla, P. K., Brown, M. S., Lamothe, R. C., et al. (2017) · eLife · doi:10.7554/elife.23268 · Cited by 81
Aird, D. R., Teng, T., Huang, C. L., Pazolli, E., Banka, D., Cheung-Ong, K., Eifert, C., Furman, C., Wu, Z. J., Seiler, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08150-5 · Cited by 79
Chemical Perturbation of Mcl-1 Pre-mRNA Splicing to Induce Apoptosis in Cancer Cells
Gao, Y., & Koide, K. (2013) · ACS Chemical Biology · doi:10.1021/cb300602j · Cited by 78
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling
Pollyea, D. A., Harris, C., Rabe, J. L., Hedin, B. R., Arras, L. D., Katz, S., Wheeler, E. C., Bejar, R. L., Walter, M. J., Jordan, C. T., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214155 · Cited by 77
Fei, D. L., Zhen, T., Durham, B. H., Ferrarone, J. R., Zhang, T., Garrett, L. J., Yoshimi, A., Abdel-Wahab, O. I., Bradley, R. K., Liu, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812669115 · Cited by 75
Xargay‐Torrent, S., López‐Guerra, M., Rosich, L., Montraveta, A., Roldán, J., Rodríguez, V., Villamor, N., Aymerich, M., Lagisetti, C., Webb, T. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4212 · Cited by 69
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
Sciarrillo, R., Wojtuszkiewicz, A., Hassouni, B. E., Funel, N., Gandellini, P., Lagerweij, T., Buonamici, S., Blijlevens, M., van der Laan, E. A. Z., Zaffaroni, N., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.025 · Cited by 68
Self-citationRbm24 Regulates Alternative Splicing Switch in Embryonic Stem Cell Cardiac Lineage Differentiation
Zhang, T., Lin, Y., Liu, J., Zhang, Z. G., Fu, W., Guo, L. Y., Pan, L., Kong, X., Zhang, M. K., Lu, Y. H., et al. (2016) · Stem Cells · doi:10.1002/stem.2366 · Cited by 67
Combinatorial regulation of alternative splicing
Shenasa, H., & Hertel, K. J. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.06.003 · Cited by 67
Aberrant splicing and drug resistance in AML
de Necochea-Campion, R., Shouse, G. P., Zhou, Q., Mirshahidi, S., & Chen, C.-S. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0315-9 · Cited by 66
Anantha, R. W., Alcivar, A. L., Ma, J., Cai, H., Simhadri, S. R., Ule, J., König, J., & Xia, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061368 · Cited by 65
Aberrant splicing in B-cell acute lymphoblastic leukemia
Black, K. L., Naqvi, A. S., Asnani, M., Hayer, K. E., Yang, S. Y., Gillespie, E. B., Bagashev, A., Pillai, V., Tasian, S. K., Gazzara, M. R., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky946 · Cited by 65
Visconte, V., Avishai, N., Mahfouz, R. Z., Tabarroki, A., Cowen, J., Sharghi-Moshtaghin, R., Hitomi, M., Rogers, H. J., Hasrouni, E., Phillips, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.170 · Cited by 64
Optimization of Antitumor Modulators of Pre-mRNA Splicing
Lagisetti, C., Palacios, G. F., Goronga, T., Freeman, B. B., Caufield, W. V., & Webb, T. R. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401370h · Cited by 64
RNA splicing and splicing regulator changes in prostate cancer pathology
Munkley, J., Livermore, K. E., Rajan, P., & Elliott, D. J. (2017) · Human Genetics · doi:10.1007/s00439-017-1792-9 · Cited by 64
Cited by
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Deguchi, Y., Kikutake, C., & Suyama, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-65035-y · Cited by 5
Metadata
- Authors
- Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 53
- Pages
- 100728
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3091597462
- Cited by
- 307
- References
- 239
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.